Interstitial Lung Disease News and Research

RSS

Interstitial lung disease (ILD) is a broad group of lung diseases comprising of more than a hundred distinct disorders. All of these involve scarring or inflammation of the interstitial lung tissue and affect the volume of oxygen that can reach the bloodstream via the respiratory system.

Increasing idiopathic pulmonary fibrosis research

IPF is an incurable lung condition with the average life expectancy following diagnosis being just three years. It’s one of the many types of interstitial lung disease (ILD). Interstitial means that the disease affects the interstitium, a lace-like network of tissue that supports the air sacs (alveoli) in your lungs.

From Asthma + Lung UK 25 Jan 2017

Researchers crack genetic code of lung tissues to identify novel targets for treating IPF

Researchers cracked the complete genetic code of individual cells in healthy and diseased human lung tissues to find potential new molecular targets for diagnosing and treating the lethal lung disease Idiopathic Pulmonary Fibrosis (IPF).

8 Dec 2016

FDG PET-CT imaging helps assess anatomical structure and metabolic activity in patients with GLILD

A new proof of concept study has shown that an imaging technique more commonly used to assess cancer patients may also be of help in assessing disease and treatment effects in patients with inflammatory diseases.

30 Nov 2016

Boehringer Ingelheim and Duke expand collaboration to create largest patient registry for idiopathic pulmonary fibrosis (IPF)

Boehringer Ingelheim Pharmaceuticals, Inc. and the Duke Clinical Research Institute (DCRI) announced today the expansion of the Idiopathic Pulmonary Fibrosis – PROspective Outcomes (IPF-PRO) Registry, a patient registry developed to uncover insights into IPF, a rare and serious lung disease. The expansion will increase the study enrollment from 300 patients at 18 study sites to 1,500 patients at approximately 45 sites, creating the largest registry of newly diagnosed IPF patients.

29 Aug 2016

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

Amgen has announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year.

6 Jul 2016

Boehringer Ingelheim presents new data on OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF)

New analyses presented at the American Thoracic Society’s 2016 annual conference (ATS 2016) further add to the efficacy and safety profile of OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF).

16 May 2016

Pulmonary hypertension impacts walking ability in SSc patients

The results of a meta-analysis show the adverse impact pulmonary hypertension has on the walking stamina of patients with systemic sclerosis.

6 May 2016

M10 peptide could help protect systemic sclerosis patients against fibrotic damage

The results of preclinical studies by investigators at the Medical University of South Carolina (MUSC) reported in the April 2016 issue of Translational Research suggest that the M10 peptide could help protect against fibrotic damage in patients with systemic sclerosis, particularly in those who develop interstitial lung diseases (ILD), its deadliest complication.

15 Apr 2016

AstraZeneca reports new Phase I extended follow-up data on osimertinib in NSCLC patients at ELCC 2016

AstraZeneca today reported new Phase I extended follow-up data on osimertinib in both first- and second-line treatment of patients with non-small cell lung cancer (NSCLC), at the European Lung Cancer Conference (ELCC) 2016. Late-breaker presentations reinforced the efficacy and safety profile for osimertinib previously seen in the AURA clinical trials programme.

15 Apr 2016

Understanding idiopathic pulmonary fibrosis: an interview with Michael Durheim, M.D.

IPF is a rare and fatal lung disease that causes permanent scarring of the lungs, leading to debilitating shortness of breath and cough in affected patients. It affects as many as 132,000 Americans, most commonly those over the age of 65.

4 Apr 2016

Systemic sclerosis: an interview with Dr Kristin Highland

Systemic sclerosis, also known as scleroderma, is a rare disease characterized by the thickening and scarring of connective tissue of multiple organs in the body

7 Mar 2016

AstraZeneca’s TAGRISSO (osimertinib) approved in EU for metastatic EGFR T790M mutation-positive NSCLC

AstraZeneca today announced that the European Commission (EC) has granted conditional marketing authorisation for TAGRISSO™ (AZD9291, osimertinib) 80mg once-daily tablets for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).

4 Feb 2016

Boehringer Ingelheim begins SENSCIS study to investigate safety, efficacy of nintedanib in patients with SSc-ILD

Boehringer Ingelheim announced today that the first person has been enrolled in the SENSCIS (Safety and Efficacy ofNintedanib in Systemic SClerosIS) study.

10 Dec 2015

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

AstraZeneca today announced that the US Food and Drug Administration has approved TAGRISSO (AZD9291) 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.

17 Nov 2015

Pitt investigators to lead $15 million federal initiative to manage breathing disorder clinical trials

The University of Pittsburgh Graduate School of Public Health and School of Medicine investigators will be leading a $15 million, five-year federal initiative to manage national clinical trials aimed at developing new treatments for breathing disorders.

5 Oct 2015

PFF, Veracyte partner on U.S. survey exploring patients' diagnostic experiences with interstitial lung diseases

The Pulmonary Fibrosis Foundation and Veracyte, Inc. announced that the organizations are partnering on a U.S. patient survey to advance understanding of patients' diagnostic experiences with interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF).

27 Aug 2015

Updated guidelines released for treatment of idiopathic pulmonary fibrosis

Updated guidelines on the treatment of idiopathic pulmonary fibrosis (IPF) have been released by an international group of leading respiratory societies, The new guidelines, issued by the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Association, were published in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

15 Jul 2015

Pretreatment ILD is a risk factor for developing radiation pneumonitis in stage I NSCLC patients

Pretreatment interstitial lung disease (ILD) is a significant risk factor for developing symptomatic and severe radiation pneumonitis in stage I non-small cell lung cancer (NSCLC) patients treated with stereotactic body radiation therapy (SBRT) alone.

12 Nov 2014

Wolters Kluwer Health wins 12 prizes at 2014 BMA Medical Book Awards

Wolters Kluwer Health, a leading global provider of information solutions for the healthcare provider and education markets, today announced that its Lippincott Williams & Wilkins textbooks and digital guides were honored with 12 prizes at the 2014 BMA Medical Book Awards.

8 Oct 2014

Ornamental birds and exposure to pigeons may contribute to hypersensitive pneumonitis

Ornamental birds and feather pillows, plus daily exposure to pigeons may contribute to the development hypersensitive pneumonitis, a disease that can cause irreversible damage to the lungs.

9 Sep 2014